Temat: "Kaplan-Meier Estimate" - OpacWWW

Skocz do pozycji: 1.

Tytuł:: Influence of radiation dose and predicted tumor invasion depth on local recurrence after definitive chemoradiotherapy for stage 0-I esophageal squamous cell carcinoma: a propensity score-weighted, retrospective, observational study.
Autorzy:: Ikawa T; Department of Radiation Oncology, Osaka International Cancer Institute, 3-1-69 Otemae, Chuo-ku, Osaka-city, Osaka, 541-8567, Japan. t_.
Ishihara R; Department of Gastrointestinal Oncology, Osaka International Cancer Institute, Osaka, Japan.
Matsueda K; Department of Gastrointestinal Oncology, Osaka International Cancer Institute, Osaka, Japan.
Konishi K; Department of Radiation Oncology, Osaka International Cancer Institute, 3-1-69 Otemae, Chuo-ku, Osaka-city, Osaka, 541-8567, Japan.
Yamamoto S; Department of Gastrointestinal Oncology, Osaka International Cancer Institute, Osaka, Japan.
Morimoto M; Department of Radiation Oncology, Osaka International Cancer Institute, 3-1-69 Otemae, Chuo-ku, Osaka-city, Osaka, 541-8567, Japan.
Kanayama N; Department of Radiation Oncology, Osaka International Cancer Institute, 3-1-69 Otemae, Chuo-ku, Osaka-city, Osaka, 541-8567, Japan.
Teshima T; Department of Radiation Oncology, Osaka International Cancer Institute, 3-1-69 Otemae, Chuo-ku, Osaka-city, Osaka, 541-8567, Japan.; Present Address: Osaka Heavy Ion Therapy Center, Osaka, Japan.; Pokaż więcej
Źródło:: BMC cancer [BMC Cancer] 2022 Mar 21; Vol. 22 (1), pp. 301. Date of Electronic Publication: 2022 Mar 21.
Typ publikacji:: Journal Article; Observational Study
MeSH Terms:: Chemoradiotherapy*
Neoplasm Recurrence, Local*
Esophageal Neoplasms/*pathology
Esophageal Neoplasms/*therapy
Esophageal Squamous Cell Carcinoma/*pathology
Esophageal Squamous Cell Carcinoma/*therapy
Aged ; Female ; Follow-Up Studies ; Humans ; Kaplan-Meier Estimate ; Male ; Middle Aged ; Neoplasm Invasiveness ; Neoplasm Staging ; Propensity Score ; Proportional Hazards Models ; Radiotherapy Dosage ; Retrospective Studies

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 2.

Tytuł:: The prognostic factor for recurrence in advanced-stage high-grade serous ovarian cancer after complete clinical remission: a nested case-control study.
Autorzy:: Wang Q; Department of Gynecology and Obstetrics, Development and Related Diseases of Women and Children Key Laboratory of Sichuan Province, Key Laboratory of Birth Defects and Related Diseases of Women and Children, Ministry of Education, West China Second Hospital, Sichuan University, Chengdu, Sichuan, 610041, People's Republic of China.; Department of Gynecology and Obstetrics, West China Second Hospital, Sichuan University, Chengdu, Sichuan, 610041, People's Republic of China.
Zheng Y; Department of Gynecology and Obstetrics, Development and Related Diseases of Women and Children Key Laboratory of Sichuan Province, Key Laboratory of Birth Defects and Related Diseases of Women and Children, Ministry of Education, West China Second Hospital, Sichuan University, Chengdu, Sichuan, 610041, People's Republic of China.; Department of Gynecology and Obstetrics, West China Second Hospital, Sichuan University, Chengdu, Sichuan, 610041, People's Republic of China.
Wang P; Department of Gynecology and Obstetrics, Development and Related Diseases of Women and Children Key Laboratory of Sichuan Province, Key Laboratory of Birth Defects and Related Diseases of Women and Children, Ministry of Education, West China Second Hospital, Sichuan University, Chengdu, Sichuan, 610041, People's Republic of China.; Department of Gynecology and Obstetrics, West China Second Hospital, Sichuan University, Chengdu, Sichuan, 610041, People's Republic of China.
Zhang J; Department of Gynecology and Obstetrics, Development and Related Diseases of Women and Children Key Laboratory of Sichuan Province, Key Laboratory of Birth Defects and Related Diseases of Women and Children, Ministry of Education, West China Second Hospital, Sichuan University, Chengdu, Sichuan, 610041, People's Republic of China.; Department of Gynecology and Obstetrics, West China Second Hospital, Sichuan University, Chengdu, Sichuan, 610041, People's Republic of China.
Liu H; Department of Gynecology and Obstetrics, Development and Related Diseases of Women and Children Key Laboratory of Sichuan Province, Key Laboratory of Birth Defects and Related Diseases of Women and Children, Ministry of Education, West China Second Hospital, Sichuan University, Chengdu, Sichuan, 610041, People's Republic of China.; Department of Gynecology and Obstetrics, West China Second Hospital, Sichuan University, Chengdu, Sichuan, 610041, People's Republic of China.
Li Q; Department of Gynecology and Obstetrics, Development and Related Diseases of Women and Children Key Laboratory of Sichuan Province, Key Laboratory of Birth Defects and Related Diseases of Women and Children, Ministry of Education, West China Second Hospital, Sichuan University, Chengdu, Sichuan, 610041, People's Republic of China.; Department of Gynecology and Obstetrics, West China Second Hospital, Sichuan University, Chengdu, Sichuan, 610041, People's Republic of China.
Yin R; Department of Gynecology and Obstetrics, Development and Related Diseases of Women and Children Key Laboratory of Sichuan Province, Key Laboratory of Birth Defects and Related Diseases of Women and Children, Ministry of Education, West China Second Hospital, Sichuan University, Chengdu, Sichuan, 610041, People's Republic of China.; Department of Gynecology and Obstetrics, West China Second Hospital, Sichuan University, Chengdu, Sichuan, 610041, People's Republic of China.
Bian C; Department of Gynecology and Obstetrics, Development and Related Diseases of Women and Children Key Laboratory of Sichuan Province, Key Laboratory of Birth Defects and Related Diseases of Women and Children, Ministry of Education, West China Second Hospital, Sichuan University, Chengdu, Sichuan, 610041, People's Republic of China.; Department of Gynecology and Obstetrics, West China Second Hospital, Sichuan University, Chengdu, Sichuan, 610041, People's Republic of China.
Peng H; Department of Gynecology and Obstetrics, Development and Related Diseases of Women and Children Key Laboratory of Sichuan Province, Key Laboratory of Birth Defects and Related Diseases of Women and Children, Ministry of Education, West China Second Hospital, Sichuan University, Chengdu, Sichuan, 610041, People's Republic of China.; Department of Gynecology and Obstetrics, West China Second Hospital, Sichuan University, Chengdu, Sichuan, 610041, People's Republic of China.
Peng Z; Department of Gynecology and Obstetrics, Development and Related Diseases of Women and Children Key Laboratory of Sichuan Province, Key Laboratory of Birth Defects and Related Diseases of Women and Children, Ministry of Education, West China Second Hospital, Sichuan University, Chengdu, Sichuan, 610041, People's Republic of China. hx_.; Department of Gynecology and Obstetrics, West China Second Hospital, Sichuan University, Chengdu, Sichuan, 610041, People's Republic of China. hx_.; Pokaż więcej
Źródło:: Journal of ovarian research [J Ovarian Res] 2021 Dec 20; Vol. 14 (1), pp. 179. Date of Electronic Publication: 2021 Dec 20.
Typ publikacji:: Journal Article
MeSH Terms:: Biomarkers, Tumor/*blood
CA-125 Antigen/*blood
Neoplasm Recurrence, Local/*blood
Ovarian Neoplasms/*blood
Adult ; Antineoplastic Agents/therapeutic use ; Case-Control Studies ; China/epidemiology ; Cytoreduction Surgical Procedures ; Female ; Humans ; Kaplan-Meier Estimate ; Middle Aged ; Neoplasm Recurrence, Local/epidemiology ; Neoplasm Recurrence, Local/therapy ; Ovarian Neoplasms/epidemiology ; Ovarian Neoplasms/therapy ; Prognosis ; Remission Induction

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 3.

Tytuł:: MRI-based radiomics and ADC values are related to recurrence of endometrial carcinoma: a preliminary analysis.
Autorzy:: Zhang K; Department of Radiation Oncology, Anhui Provincial Hospital Affiliated to Anhui Medical University, Hefei, 230001, China.
Zhang Y; Department of Radiation Oncology, Anhui Provincial Hospital Affiliated to Anhui Medical University, Hefei, 230001, China.
Fang X; Department of Radiology, First Affiliated Hospital of University of Science and Technology of China, Anhui Provincial Cancer Hospital, Hefei, 230031, China.
Dong J; Department of Radiation Oncology, Anhui Provincial Hospital Affiliated to Anhui Medical University, Hefei, 230001, China. .; Department of Radiology, First Affiliated Hospital of University of Science and Technology of China, Anhui Provincial Cancer Hospital, Hefei, 230031, China. .
Qian L; Department of Radiation Oncology, Anhui Provincial Hospital Affiliated to Anhui Medical University, Hefei, 230001, China. .; Department of Radiation Oncology, First Affiliated Hospital of University of Science and Technology of China, Hefei, 230001, China. .; Pokaż więcej
Źródło:: BMC cancer [BMC Cancer] 2021 Nov 24; Vol. 21 (1), pp. 1266. Date of Electronic Publication: 2021 Nov 24.
Typ publikacji:: Journal Article
MeSH Terms:: Neoplasm Recurrence, Local*
Diffusion Magnetic Resonance Imaging/*methods
Endometrial Neoplasms/*diagnostic imaging
Analysis of Variance ; Diffusion Magnetic Resonance Imaging/statistics & numerical data ; Disease-Free Survival ; Endometrial Neoplasms/pathology ; Endometrial Neoplasms/surgery ; Female ; Humans ; Kaplan-Meier Estimate ; Middle Aged ; Neoplasm Staging ; Preliminary Data ; ROC Curve ; Retrospective Studies ; Risk Factors

Czasopismo naukowe

na półce

Pełny tekst Szczegóły

Skocz do pozycji: 4.

Tytuł:: A novel serum biomarker quintet reveals added prognostic value when combined with standard clinical parameters in prostate cancer patients by predicting biochemical recurrence and adverse pathology.
Autorzy:: Athanasiou A; Proteomedix AG, Zurich-Schlieren, Switzerland.
Tennstedt P; Martini-Klinik, University Hospital Hamburg-Eppendorf, Hamburg, Germany.
Wittig A; Proteomedix AG, Zurich-Schlieren, Switzerland.
Huber R; Proteomedix AG, Zurich-Schlieren, Switzerland.
Straub O; Proteomedix AG, Zurich-Schlieren, Switzerland.
Schiess R; Proteomedix AG, Zurich-Schlieren, Switzerland.
Steuber T; Martini-Klinik, University Hospital Hamburg-Eppendorf, Hamburg, Germany.; Pokaż więcej
Źródło:: PloS one [PLoS One] 2021 Nov 12; Vol. 16 (11), pp. e0259093. Date of Electronic Publication: 2021 Nov 12 (Print Publication: 2021).
Typ publikacji:: Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:: Neoplasm Recurrence, Local/*blood
Prostate-Specific Antigen/*blood
Prostatectomy/*methods
Prostatic Neoplasms/*blood
Prostatic Neoplasms/*surgery
Adult ; Aged ; Antigens, Neoplasm/blood ; Biomarkers, Tumor/blood ; Germany/epidemiology ; Humans ; Kaplan-Meier Estimate ; Male ; Middle Aged ; Neoplasm Recurrence, Local/epidemiology ; Neoplasm Staging ; Prognosis ; Prostatic Neoplasms/epidemiology ; Prostatic Neoplasms/pathology ; Retrospective Studies ; Risk Assessment ; Treatment Outcome

Czasopismo naukowe

na półce

Pełny tekst Szczegóły

Skocz do pozycji: 5.

Tytuł:: Optimal pathological response after neoadjuvant chemotherapy for muscle-invasive bladder cancer: results from a global, multicentre collaboration.
Autorzy:: Ravi P; Dana-Farber Cancer Institute, Boston, MA, USA.
Pond GR; McMaster University, Hamilton, ON, Canada.
Diamantopoulos LN; Fred Hutchinson Cancer Research Center Seattle, University of Washington, Seattle, WA, USA.; University of Pittsburg Medical Center, Pittsburgh, PA, USA.
Su C; University of Michigan, Ann Arbor, MI, USA.
Alva A; University of Michigan, Ann Arbor, MI, USA.
Jain RK; Moffitt Cancer Center, Tampa, FL, USA.
Skelton WP 4th; Moffitt Cancer Center, Tampa, FL, USA.
Gupta S; University of Utah's Huntsman Cancer Institute, Salt Lake City, UT, USA.
Tward JD; University of Utah's Huntsman Cancer Institute, Salt Lake City, UT, USA.
Olson KM; Mayo Clinic College of Medicine, Scottsdale, AZ, USA.
Singh P; Mayo Clinic College of Medicine, Scottsdale, AZ, USA.
Grunewald CM; Department of Urology, Medical Faculty, Heinrich-Heine-University Düsseldorf, Düsseldorf, Germany.
Niegisch G; Department of Urology, Medical Faculty, Heinrich-Heine-University Düsseldorf, Düsseldorf, Germany.
Lee JL; Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.
Gallina A; Vita-Salute San Raffaele University, Milan, Italy.
Bandini M; Vita-Salute San Raffaele University, Milan, Italy.
Necchi A; Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.
Mossanen M; Dana-Farber Cancer Institute, Boston, MA, USA.; Brigham and Women's Hospital, Boston, MA, USA.
McGregor BA; Dana-Farber Cancer Institute, Boston, MA, USA.
Curran C; Dana-Farber Cancer Institute, Boston, MA, USA.
Grivas P; Fred Hutchinson Cancer Research Center Seattle, University of Washington, Seattle, WA, USA.
Sonpavde GP; Dana-Farber Cancer Institute, Boston, MA, USA.; Pokaż więcej
Źródło:: BJU international [BJU Int] 2021 Nov; Vol. 128 (5), pp. 607-614. Date of Electronic Publication: 2021 May 18.
Typ publikacji:: Journal Article; Multicenter Study
MeSH Terms:: Antineoplastic Combined Chemotherapy Protocols/*therapeutic use
Neoplasm Recurrence, Local/*pathology
Urinary Bladder Neoplasms/*drug therapy
Urinary Bladder Neoplasms/*pathology
Adult ; Aged ; Aged, 80 and over ; Antineoplastic Combined Chemotherapy Protocols/administration & dosage ; Chemotherapy, Adjuvant ; Cisplatin/administration & dosage ; Cystectomy ; Deoxycytidine/administration & dosage ; Deoxycytidine/analogs & derivatives ; Doxorubicin/administration & dosage ; Female ; Humans ; Internationality ; Kaplan-Meier Estimate ; Male ; Methotrexate/administration & dosage ; Middle Aged ; Muscle, Smooth/pathology ; Neoadjuvant Therapy ; Neoplasm Invasiveness ; Neoplasm Metastasis ; Neoplasm Staging ; Proportional Hazards Models ; Risk Factors ; Time Factors ; Urinary Bladder/pathology ; Urinary Bladder Neoplasms/surgery ; Vinblastine/administration & dosage ; Gemcitabine
SCR Protocol:: M-VAC protocol

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 6.

Tytuł:: Identification of patients at risk for biochemical recurrence after radical prostatectomy with intra-operative frozen section.
Autorzy:: Tully KH; Department of Urology and Neurourology, Marien Hospital Herne, Ruhr-University Bochum, Herne, Germany.
Schulmeyer M; Department of Urology and Neurourology, Marien Hospital Herne, Ruhr-University Bochum, Herne, Germany.
Hanske J; Department of Urology and Neurourology, Marien Hospital Herne, Ruhr-University Bochum, Herne, Germany.
Reike MJ; Department of Urology and Neurourology, Marien Hospital Herne, Ruhr-University Bochum, Herne, Germany.
Brock M; Department of Urology and Neurourology, Marien Hospital Herne, Ruhr-University Bochum, Herne, Germany.
Moritz R; Department of Urology and Neurourology, Marien Hospital Herne, Ruhr-University Bochum, Herne, Germany.
Jütte H; Institute of Pathology, Ruhr-University Bochum, Bochum, Germany.
Tannapfel A; Institute of Pathology, Ruhr-University Bochum, Bochum, Germany.
von Bodman C; Department of Urology and Neurourology, Marien Hospital Herne, Ruhr-University Bochum, Herne, Germany.
Noldus J; Department of Urology and Neurourology, Marien Hospital Herne, Ruhr-University Bochum, Herne, Germany.
Palisaar RJ; Department of Urology and Neurourology, Marien Hospital Herne, Ruhr-University Bochum, Herne, Germany.
Roghmann F; Department of Urology and Neurourology, Marien Hospital Herne, Ruhr-University Bochum, Herne, Germany.; Pokaż więcej
Źródło:: BJU international [BJU Int] 2021 Nov; Vol. 128 (5), pp. 598-606. Date of Electronic Publication: 2021 Jun 06.
Typ publikacji:: Journal Article
MeSH Terms:: Margins of Excision*
Neoplasm Recurrence, Local/*blood
Prostate-Specific Antigen/*blood
Prostatic Neoplasms/*pathology
Prostatic Neoplasms/*surgery
Aged ; Follow-Up Studies ; Frozen Sections ; Humans ; Intraoperative Period ; Kaplan-Meier Estimate ; Male ; Middle Aged ; Neoplasm Grading ; Neoplasm Recurrence, Local/pathology ; Proportional Hazards Models ; Prostatectomy ; Prostatic Neoplasms/blood ; Retrospective Studies ; Risk Assessment ; Risk Factors

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 7.

Tytuł:: Identification and characterization of a 25-lncRNA prognostic signature for early recurrence in hepatocellular carcinoma.
Autorzy:: Fu Y; Affiliated Zhoupu Hospital, Shanghai University of Medicine and Health Sciences, Shanghai, 201318, China.; Shanghai Key Laboratory of Molecular Imaging, Collaborative Innovation Center for Biomedicines, Shanghai University of Medicine and Health Sciences, Shanghai, 201318, China.; School of Medical Instruments, Shanghai University of Medicine and Health Sciences, Shanghai, 201318, China.
Wei X; Nanjing University of Traditional Chinese Medicine, Nanjing, 210000, China.
Han Q; Affiliated Zhoupu Hospital, Shanghai University of Medicine and Health Sciences, Shanghai, 201318, China.; Shanghai Key Laboratory of Molecular Imaging, Collaborative Innovation Center for Biomedicines, Shanghai University of Medicine and Health Sciences, Shanghai, 201318, China.
Le J; Affiliated Zhoupu Hospital, Shanghai University of Medicine and Health Sciences, Shanghai, 201318, China.; Shanghai Key Laboratory of Molecular Imaging, Collaborative Innovation Center for Biomedicines, Shanghai University of Medicine and Health Sciences, Shanghai, 201318, China.
Ma Y; Shanghai Key Laboratory of Molecular Imaging, Collaborative Innovation Center for Biomedicines, Shanghai University of Medicine and Health Sciences, Shanghai, 201318, China.
Lin X; Shanghai Key Laboratory of Molecular Imaging, Collaborative Innovation Center for Biomedicines, Shanghai University of Medicine and Health Sciences, Shanghai, 201318, China.
Xu Y; Graduate School of Art and Sciences, Columbia University, New York, NY, 10027, USA.
Liu N; Department of Clinical Oncology, Taian City Central Hospital, Taian, 271000, Shandong, China.
Wang X; Department of General Surgery, Nanjing General Hospital of Nanjing Military Command, Nanjing, 210000, China.
Kong X; Institute of Clinical Immunology, Department of Liver Diseases, Central Laboratory, Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine, Shanghai, 200021, China.
Gu J; Department of Transplantation, Xinhua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, 200092, China. .
Tong Y; Department of Liver Surgery, Renji Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, 200127, China. .
Wu H; Affiliated Zhoupu Hospital, Shanghai University of Medicine and Health Sciences, Shanghai, 201318, China. .; Shanghai Key Laboratory of Molecular Imaging, Collaborative Innovation Center for Biomedicines, Shanghai University of Medicine and Health Sciences, Shanghai, 201318, China. .; Pokaż więcej
Źródło:: BMC cancer [BMC Cancer] 2021 Oct 30; Vol. 21 (1), pp. 1165. Date of Electronic Publication: 2021 Oct 30.
Typ publikacji:: Journal Article
MeSH Terms:: Gene Expression Profiling*
Carcinoma, Hepatocellular/*genetics
Liver Neoplasms/*genetics
Neoplasm Recurrence, Local/*genetics
RNA, Long Noncoding/*genetics
Carcinoma, Hepatocellular/mortality ; Carcinoma, Hepatocellular/pathology ; Carcinoma, Hepatocellular/therapy ; DNA Repair ; Disease-Free Survival ; G2 Phase Cell Cycle Checkpoints ; Genes, myc ; Humans ; Immunotherapy ; Kaplan-Meier Estimate ; Liver Neoplasms/mortality ; Liver Neoplasms/pathology ; Liver Neoplasms/therapy ; Lymphocytes, Tumor-Infiltrating ; Neoplasm Recurrence, Local/mortality ; Neoplasm Recurrence, Local/pathology ; Neoplasm Recurrence, Local/therapy ; Prognosis ; Proportional Hazards Models ; RNA, Long Noncoding/analysis ; ROC Curve ; Risk Factors ; alpha-Fetoproteins/analysis

Czasopismo naukowe

na półce

Pełny tekst Szczegóły

Skocz do pozycji: 8.

Tytuł:: Gene signatures predict biochemical recurrence-free survival in primary prostate cancer patients after radical therapy.
Autorzy:: Su Q; Beijing Advanced Innovation Center for Big Data-Based Precision Medicine, School of Medicine and Engineering, Beihang University, Beijing, China.; Clinical Laboratory Medicine, Beijing Shijitan Hospital, Capital Medical University, Beijing, China.; Beijing Key Laboratory of Urinary Cellular Molecular Diagnostics, Beijing, China.; Key Laboratory of Big Data-Based Precision Medicine (Beihang University), Ministry of Industry and Information Technology, Beijing, China.
Liu Z; CAS Key Laboratory of Molecular Imaging, Beijing Key Laboratory of Molecular Imaging, the State Key Laboratory of Management and Control for Complex Systems, Institute of Automation, Chinese Academy of Sciences, Beijing, China.; CAS Center for Excellence in Brain Science and Intelligence Technology, Institute of Automation, Chinese Academy of Sciences, Beijing, China.; School of Artificial Intelligence, University of Chinese Academy of Sciences, Beijing, China.
Chen C; Beijing Advanced Innovation Center for Big Data-Based Precision Medicine, School of Medicine and Engineering, Beihang University, Beijing, China.; Key Laboratory of Big Data-Based Precision Medicine (Beihang University), Ministry of Industry and Information Technology, Beijing, China.
Gao H; Beijing Advanced Innovation Center for Big Data-Based Precision Medicine, School of Medicine and Engineering, Beihang University, Beijing, China.; Key Laboratory of Big Data-Based Precision Medicine (Beihang University), Ministry of Industry and Information Technology, Beijing, China.
Zhu Y; Beijing Advanced Innovation Center for Big Data-Based Precision Medicine, School of Medicine and Engineering, Beihang University, Beijing, China.; Key Laboratory of Big Data-Based Precision Medicine (Beihang University), Ministry of Industry and Information Technology, Beijing, China.
Wang L; Beijing Advanced Innovation Center for Big Data-Based Precision Medicine, School of Medicine and Engineering, Beihang University, Beijing, China.; Key Laboratory of Big Data-Based Precision Medicine (Beihang University), Ministry of Industry and Information Technology, Beijing, China.
Pan M; Beijing Advanced Innovation Center for Big Data-Based Precision Medicine, School of Medicine and Engineering, Beihang University, Beijing, China.; Key Laboratory of Big Data-Based Precision Medicine (Beihang University), Ministry of Industry and Information Technology, Beijing, China.
Liu J; Beijing Advanced Innovation Center for Big Data-Based Precision Medicine, School of Medicine and Engineering, Beihang University, Beijing, China.; Key Laboratory of Big Data-Based Precision Medicine (Beihang University), Ministry of Industry and Information Technology, Beijing, China.
Yang X; CAS Key Laboratory of Molecular Imaging, Beijing Key Laboratory of Molecular Imaging, the State Key Laboratory of Management and Control for Complex Systems, Institute of Automation, Chinese Academy of Sciences, Beijing, China.; School of Artificial Intelligence, University of Chinese Academy of Sciences, Beijing, China.
Tian J; Beijing Advanced Innovation Center for Big Data-Based Precision Medicine, School of Medicine and Engineering, Beihang University, Beijing, China.; Key Laboratory of Big Data-Based Precision Medicine (Beihang University), Ministry of Industry and Information Technology, Beijing, China.; CAS Key Laboratory of Molecular Imaging, Beijing Key Laboratory of Molecular Imaging, the State Key Laboratory of Management and Control for Complex Systems, Institute of Automation, Chinese Academy of Sciences, Beijing, China.; CAS Center for Excellence in Brain Science and Intelligence Technology, Institute of Automation, Chinese Academy of Sciences, Beijing, China.; Engineering Research Center of Molecular and Neuro Imaging of Ministry of Education, School of Life Science and Technology, Xidian University, Xi'an, Shaanxi, China.; Pokaż więcej
Źródło:: Cancer medicine [Cancer Med] 2021 Sep; Vol. 10 (18), pp. 6492-6502. Date of Electronic Publication: 2021 Aug 28.
Typ publikacji:: Journal Article; Research Support, Non-U.S. Gov't; Validation Study
MeSH Terms:: Nomograms*
Transcriptome*
Biomarkers, Tumor/*genetics
Neoplasm Recurrence, Local/*epidemiology
Prostatic Neoplasms/*mortality
Datasets as Topic ; Disease-Free Survival ; Follow-Up Studies ; Gene Expression Profiling ; Gene Expression Regulation, Neoplastic ; Humans ; Kallikreins/blood ; Kaplan-Meier Estimate ; Male ; Neoplasm Grading ; Neoplasm Recurrence, Local/blood ; Neoplasm Recurrence, Local/diagnosis ; Neoplasm Recurrence, Local/genetics ; Predictive Value of Tests ; Prostate-Specific Antigen/blood ; Prostatic Neoplasms/blood ; Prostatic Neoplasms/genetics ; Prostatic Neoplasms/therapy ; ROC Curve ; Risk Assessment/methods ; Risk Assessment/statistics & numerical data

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 9.

Tytuł:: Improved survival with enasidenib versus standard of care in relapsed/refractory acute myeloid leukemia associated with IDH2 mutations using historical data and propensity score matching analysis.
Autorzy:: de Botton S; Departement d'hematologie, Institut Gustave Roussy, Villejuif, France.
Brandwein JM; University of Alberta, Edmonton, Alberta, Canada.
Wei AH; Alfred Hospital and Monash University, Melbourne, Australia.
Pigneux A; CHU Bordeaux, Hôpital du Haut Lévêque, Bordeaux, France.
Quesnel B; CHU Lille, Lille, France.
Thomas X; Centre Hospitalier Lyon Sud, Pierre Bénite, France.
Legrand O; APHP, Hôpital Saint-Antoine, Paris, France.
Recher C; CHU de Toulouse, Université de Toulouse III Paul Sabatier, Toulouse, France.
Chantepie S; CHU de Caen, Caen, France.
Hunault-Berger M; CHU Angers, Angers, France.
Boissel N; Hôpital Saint-Louis, Paris, France.
Nehme SA; Celgene International, a Bristol Myers Squibb Company, Boudry, Switzerland.
Frattini MG; Bristol Myers Squibb, Summit, New Jersey, USA.
Tosolini A; Bristol Myers Squibb, Summit, New Jersey, USA.
Marion-Gallois R; Bristol Myers Squibb, Summit, New Jersey, USA.
Wang JJ; Bristol Myers Squibb, Summit, New Jersey, USA.
Cameron C; Cornerstone Research Group, Burlington, Ontario, Canada.
Siddiqui M; Cornerstone Research Group, Burlington, Ontario, Canada.
Hutton B; Ottawa Hospital Research Institute, Ottawa, Ontario, Canada.
Milkovich G; RJM Group LLC, Crown Point, Indiana, USA.
Stein EM; Memorial Sloan Kettering Cancer Center, New York, New York, USA.; Pokaż więcej
Źródło:: Cancer medicine [Cancer Med] 2021 Sep; Vol. 10 (18), pp. 6336-6343. Date of Electronic Publication: 2021 Aug 24.
Typ publikacji:: Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:: Aminopyridines/*therapeutic use
Isocitrate Dehydrogenase/*antagonists & inhibitors
Leukemia, Myeloid, Acute/*drug therapy
Neoplasm Recurrence, Local/*drug therapy
Standard of Care/*statistics & numerical data
Triazines/*therapeutic use
Adolescent ; Adult ; Aged ; Aminopyridines/pharmacology ; Clinical Trials, Phase I as Topic/statistics & numerical data ; Clinical Trials, Phase II as Topic/statistics & numerical data ; Drug Resistance, Neoplasm/genetics ; Female ; France/epidemiology ; Humans ; Isocitrate Dehydrogenase/genetics ; Kaplan-Meier Estimate ; Leukemia, Myeloid, Acute/genetics ; Leukemia, Myeloid, Acute/mortality ; Male ; Middle Aged ; Multicenter Studies as Topic ; Mutation ; Neoplasm Recurrence, Local/genetics ; Neoplasm Recurrence, Local/mortality ; Observational Studies as Topic ; Propensity Score ; Treatment Outcome ; Triazines/pharmacology ; Young Adult

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 10.

Tytuł:: Novel Prognostic Score for recurrent or metastatic head and neck cancer patients treated with Nivolumab.
Autorzy:: Minohara K; Department of Otorhinolaryngology, Head and Neck Surgery, Nagoya City University Graduate School of Medical Sciences, 1 Kawasumi, Mizuho-cho, Mizuho-ku, Nagoya, Aichi, 467-8601, Japan.
Matoba T; Department of Otorhinolaryngology, Head and Neck Surgery, Nagoya City University Graduate School of Medical Sciences, 1 Kawasumi, Mizuho-cho, Mizuho-ku, Nagoya, Aichi, 467-8601, Japan.
Kawakita D; Department of Otorhinolaryngology, Head and Neck Surgery, Nagoya City University Graduate School of Medical Sciences, 1 Kawasumi, Mizuho-cho, Mizuho-ku, Nagoya, Aichi, 467-8601, Japan. .
Takano G; Department of Otorhinolaryngology, Head and Neck Surgery, Nagoya City University Graduate School of Medical Sciences, 1 Kawasumi, Mizuho-cho, Mizuho-ku, Nagoya, Aichi, 467-8601, Japan.
Oguri K; Department of Otorhinolaryngology, Konan Kosei Hospital, Konan, Japan.
Murashima A; Department of Otorhinolaryngology, Head and Neck Surgery, Nagoya City University Graduate School of Medical Sciences, 1 Kawasumi, Mizuho-cho, Mizuho-ku, Nagoya, Aichi, 467-8601, Japan.
Nakai K; Department of Otorhinolaryngology, Head and Neck Surgery, Nagoya City University Graduate School of Medical Sciences, 1 Kawasumi, Mizuho-cho, Mizuho-ku, Nagoya, Aichi, 467-8601, Japan.
Iwaki S; Department of Otorhinolaryngology, Head and Neck Surgery, Nagoya City University Graduate School of Medical Sciences, 1 Kawasumi, Mizuho-cho, Mizuho-ku, Nagoya, Aichi, 467-8601, Japan.
Hojo W; Department of Otorhinolaryngology, Head and Neck Surgery, Nagoya City University Graduate School of Medical Sciences, 1 Kawasumi, Mizuho-cho, Mizuho-ku, Nagoya, Aichi, 467-8601, Japan.
Matsumura A; Department of Otorhinolaryngology, Head and Neck Surgery, Nagoya City University Graduate School of Medical Sciences, 1 Kawasumi, Mizuho-cho, Mizuho-ku, Nagoya, Aichi, 467-8601, Japan.
Ozaki S; Department of Otorhinolaryngology, Konan Kosei Hospital, Konan, Japan.
Ozawa T; Department of Otorhinolaryngology, Toyohashi Municipal Hospital, Toyohashi, Japan.
Harata I; Department of Otorhinolaryngology, Kainan Hospital, Yatomi, Japan.
Tanaka N; Department of Otorhinolaryngology, Toyota Kosei Hospital, Toyota, Japan.
Maseki S; Department of Otorhinolaryngology, Toyota Kosei Hospital, Toyota, Japan.
Tsuge H; Department of Otorhinolaryngology, Anjo Kosei Hospital, Anjo, Japan.
Imaizumi S; Department of Otorhinolaryngology, Anjo Kosei Hospital, Anjo, Japan.
Mitsuya S; Department of Otorhinolaryngology, Anjo Kosei Hospital, Anjo, Japan.
Moribe K; Department of Otorhinolaryngology, Ichinomiya Municipal Hospital, Ichinomiya, Japan.
Esaki S; Department of Otorhinolaryngology, Head and Neck Surgery, Nagoya City University Graduate School of Medical Sciences, 1 Kawasumi, Mizuho-cho, Mizuho-ku, Nagoya, Aichi, 467-8601, Japan.
Iwasaki S; Department of Otorhinolaryngology, Head and Neck Surgery, Nagoya City University Graduate School of Medical Sciences, 1 Kawasumi, Mizuho-cho, Mizuho-ku, Nagoya, Aichi, 467-8601, Japan.; Pokaż więcej
Źródło:: Scientific reports [Sci Rep] 2021 Aug 20; Vol. 11 (1), pp. 16992. Date of Electronic Publication: 2021 Aug 20.
Typ publikacji:: Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:: Head and Neck Neoplasms/*diagnosis
Head and Neck Neoplasms/*drug therapy
Neoplasm Recurrence, Local/*pathology
Nivolumab/*therapeutic use
Adult ; Aged ; Female ; Humans ; Kaplan-Meier Estimate ; Male ; Middle Aged ; Neoplasm Metastasis ; Prognosis ; Progression-Free Survival ; Treatment Outcome

Czasopismo naukowe

na półce

Pełny tekst Szczegóły

Skocz do pozycji: 11.

Tytuł:: Overexpression of claspin promotes docetaxel resistance and is associated with prostate-specific antigen recurrence in prostate cancer.
Autorzy:: Babasaki T; Department of Molecular Pathology, Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima, Japan.; Department of Urology, Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima, Japan.
Sentani K; Department of Molecular Pathology, Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima, Japan.
Sekino Y; Department of Urology, Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima, Japan.
Kobayashi G; Department of Pathology, Kure Kyosai Hospital, Federation of National Public Service Personnel Mutual Aid Associations, Hiroshima, Japan.
Thang Pham Q; Department of Molecular Pathology, Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima, Japan.
Katsuya N; Department of Molecular Pathology, Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima, Japan.
Akabane S; Department of Molecular Pathology, Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima, Japan.
Taniyama D; Department of Molecular Pathology, Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima, Japan.
Hayashi T; Department of Urology, Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima, Japan.
Shiota M; Department of Urology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.
Oue N; Department of Molecular Pathology, Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima, Japan.
Teishima J; Department of Urology, Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima, Japan.
Matsubara A; Department of Urology, Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima, Japan.
Yasui W; Department of Molecular Pathology, Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima, Japan.; Pokaż więcej
Źródło:: Cancer medicine [Cancer Med] 2021 Aug; Vol. 10 (16), pp. 5574-5588. Date of Electronic Publication: 2021 Jul 09.
Typ publikacji:: Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:: Adaptor Proteins, Signal Transducing/*genetics
Docetaxel/*pharmacology
Drug Resistance, Neoplasm/*genetics
Neoplasm Recurrence, Local/*genetics
Prostatic Neoplasms/*drug therapy
Aged ; Datasets as Topic ; Disease-Free Survival ; Docetaxel/therapeutic use ; Gene Expression Profiling ; Gene Expression Regulation, Neoplastic ; Gene Knockdown Techniques ; Humans ; Kallikreins/blood ; Kaplan-Meier Estimate ; Male ; Neoplasm Grading ; Neoplasm Recurrence, Local/blood ; Neoplasm Recurrence, Local/diagnosis ; Neoplasm Recurrence, Local/epidemiology ; PC-3 Cells ; Prostate-Specific Antigen/blood ; Prostatic Neoplasms/blood ; Prostatic Neoplasms/genetics ; Prostatic Neoplasms/mortality ; Retrospective Studies ; Up-Regulation

Czasopismo naukowe

na półce

Pełny tekst Szczegóły

Skocz do pozycji: 12.

Tytuł:: Fragility of randomized trials supporting cancer drug approvals stratified by approval pathway and review designations.
Autorzy:: Wilson BE; Princess Margaret Cancer Centre, Department of Medical Oncology, University of Toronto, Toronto, ON, Canada.; University of New South Wales, Kensington, NSW, Australia.
Desnoyers A; Princess Margaret Cancer Centre, Department of Medical Oncology, University of Toronto, Toronto, ON, Canada.
Nadler MB; Princess Margaret Cancer Centre, Department of Medical Oncology, University of Toronto, Toronto, ON, Canada.
Tibau A; Oncology Department, Hospital de la Santa Creu i Sant Pau, Institut d'Investigació Biomèdica Sant Pau, and Universitat Autònoma de Barcelona, Barcelona, Catalonia, Spain.
Amir E; Princess Margaret Cancer Centre, Department of Medical Oncology, University of Toronto, Toronto, ON, Canada.; Pokaż więcej
Źródło:: Cancer medicine [Cancer Med] 2021 Aug; Vol. 10 (16), pp. 5405-5414. Date of Electronic Publication: 2021 Jul 28.
Typ publikacji:: Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:: Antineoplastic Agents/*therapeutic use
Drug Approval/*statistics & numerical data
Neoplasm Recurrence, Local/*epidemiology
Neoplasms/*drug therapy
Randomized Controlled Trials as Topic/*statistics & numerical data
Consent Forms/statistics & numerical data ; Disease-Free Survival ; Humans ; Kaplan-Meier Estimate ; Lost to Follow-Up ; Neoplasm Recurrence, Local/prevention & control ; Neoplasms/mortality ; Progression-Free Survival ; Randomized Controlled Trials as Topic/standards ; Sample Size ; Time Factors ; United States ; United States Food and Drug Administration/standards

Czasopismo naukowe

na półce

Pełny tekst Szczegóły

Skocz do pozycji: 13.

Tytuł:: Combination of GP88 Expression in Tumor Cells and Tumor-Infiltrating Immune Cells Is an Independent Prognostic Factor for Bladder Cancer Patients.
Autorzy:: Eckstein M; Institute of Pathology, University Hospital Erlangen, FAU Erlangen-Nürnberg, 91054 Erlangen, Germany.; Bridge Consortium, 68135 Mannheim, Germany.; Comprehensive Cancer Center Erlangen-EMN (CCC ER-EMN), 91054 Erlangen, Germany.
Lieb V; Comprehensive Cancer Center Erlangen-EMN (CCC ER-EMN), 91054 Erlangen, Germany.; Department of Urology and Pediatric Urology, University Hospital Erlangen, FAU Erlangen-Nürnberg, 91054 Erlangen, Germany.
Jung R; Institute of Pathology, University Hospital Erlangen, FAU Erlangen-Nürnberg, 91054 Erlangen, Germany.; Comprehensive Cancer Center Erlangen-EMN (CCC ER-EMN), 91054 Erlangen, Germany.
Sikic D; Bridge Consortium, 68135 Mannheim, Germany.; Comprehensive Cancer Center Erlangen-EMN (CCC ER-EMN), 91054 Erlangen, Germany.; Department of Urology and Pediatric Urology, University Hospital Erlangen, FAU Erlangen-Nürnberg, 91054 Erlangen, Germany.
Weigelt K; Comprehensive Cancer Center Erlangen-EMN (CCC ER-EMN), 91054 Erlangen, Germany.; Department of Urology and Pediatric Urology, University Hospital Erlangen, FAU Erlangen-Nürnberg, 91054 Erlangen, Germany.
Stöhr R; Institute of Pathology, University Hospital Erlangen, FAU Erlangen-Nürnberg, 91054 Erlangen, Germany.; Bridge Consortium, 68135 Mannheim, Germany.; Comprehensive Cancer Center Erlangen-EMN (CCC ER-EMN), 91054 Erlangen, Germany.
Geppert C; Institute of Pathology, University Hospital Erlangen, FAU Erlangen-Nürnberg, 91054 Erlangen, Germany.; Comprehensive Cancer Center Erlangen-EMN (CCC ER-EMN), 91054 Erlangen, Germany.
Weyerer V; Institute of Pathology, University Hospital Erlangen, FAU Erlangen-Nürnberg, 91054 Erlangen, Germany.; Comprehensive Cancer Center Erlangen-EMN (CCC ER-EMN), 91054 Erlangen, Germany.
Bertz S; Institute of Pathology, University Hospital Erlangen, FAU Erlangen-Nürnberg, 91054 Erlangen, Germany.; Comprehensive Cancer Center Erlangen-EMN (CCC ER-EMN), 91054 Erlangen, Germany.
Serrero G; A&G Pharmaceutical Inc., Columbia, MD 21045, USA.; Program in Oncology, University of Maryland Greenebaum Comprehensive Cancer Center, Baltimore, MD 21201, USA.
Yue B; A&G Pharmaceutical Inc., Columbia, MD 21045, USA.
Hartmann A; Institute of Pathology, University Hospital Erlangen, FAU Erlangen-Nürnberg, 91054 Erlangen, Germany.; Bridge Consortium, 68135 Mannheim, Germany.; Comprehensive Cancer Center Erlangen-EMN (CCC ER-EMN), 91054 Erlangen, Germany.
Wullich B; Bridge Consortium, 68135 Mannheim, Germany.; Comprehensive Cancer Center Erlangen-EMN (CCC ER-EMN), 91054 Erlangen, Germany.; Department of Urology and Pediatric Urology, University Hospital Erlangen, FAU Erlangen-Nürnberg, 91054 Erlangen, Germany.
Taubert H; Bridge Consortium, 68135 Mannheim, Germany.; Comprehensive Cancer Center Erlangen-EMN (CCC ER-EMN), 91054 Erlangen, Germany.; Department of Urology and Pediatric Urology, University Hospital Erlangen, FAU Erlangen-Nürnberg, 91054 Erlangen, Germany.
Wach S; Bridge Consortium, 68135 Mannheim, Germany.; Comprehensive Cancer Center Erlangen-EMN (CCC ER-EMN), 91054 Erlangen, Germany.; Department of Urology and Pediatric Urology, University Hospital Erlangen, FAU Erlangen-Nürnberg, 91054 Erlangen, Germany.; Pokaż więcej
Źródło:: Cells [Cells] 2021 Jul 15; Vol. 10 (7). Date of Electronic Publication: 2021 Jul 15.
Typ publikacji:: Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:: Biomarkers, Tumor/*metabolism
Neoplasm Recurrence, Local/*diagnosis
Urinary Bladder Neoplasms/*diagnosis
Urinary Bladder Neoplasms/*pathology
Adult ; Aged ; Aged, 80 and over ; Disease-Free Survival ; Female ; Humans ; Immunohistochemistry/methods ; Kaplan-Meier Estimate ; Male ; Middle Aged ; Neoplasm Recurrence, Local/pathology ; Prognosis ; Urinary Bladder Neoplasms/metabolism

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 14.

Tytuł:: Apatinib treatment efficiently delays biochemical-only recurrent ovarian cancer progression.
Autorzy:: Wang Z; Institute of Cancer, Xinqiao Hospital, Third Military Medical University, Chongqing 400037, People's Republic of China.
Huang Y; Department of Obstetrics and Gynecology, Xinqiao Hospital, Third Military Medical University, Chongqing 400037, People's Republic of China.
Long L; Department of Obstetrics and Gynecology, Xinqiao Hospital, Third Military Medical University, Chongqing 400037, People's Republic of China.
Zhou L; Department of Obstetrics and Gynecology, Southwest Hospital, Third Military Medical University, Chongqing 400038, People's Republic of China.
Huang Y; Department of Obstetrics and Gynecology, Xinqiao Hospital, Third Military Medical University, Chongqing 400037, People's Republic of China.
Gan L; Department of Obstetrics and Gynecology, Xinqiao Hospital, Third Military Medical University, Chongqing 400037, People's Republic of China.
Pu A; Department of Obstetrics and Gynecology, Xinqiao Hospital, Third Military Medical University, Chongqing 400037, People's Republic of China.
Li S; Department of Obstetrics and Gynecology, Xinqiao Hospital, Third Military Medical University, Chongqing 400037, People's Republic of China.
Xie R; Department of Obstetrics and Gynecology, Xinqiao Hospital, Third Military Medical University, Chongqing 400037, People's Republic of China. .; Pokaż więcej
Źródło:: Journal of ovarian research [J Ovarian Res] 2021 Jul 12; Vol. 14 (1), pp. 91. Date of Electronic Publication: 2021 Jul 12.
Typ publikacji:: Journal Article
MeSH Terms:: Antineoplastic Agents/*therapeutic use
Neoplasm Recurrence, Local/*drug therapy
Ovarian Neoplasms/*drug therapy
Protein Kinase Inhibitors/*therapeutic use
Pyridines/*therapeutic use
Adult ; Aged ; Disease Progression ; Female ; Humans ; Kaplan-Meier Estimate ; Middle Aged ; Neoplasm Recurrence, Local/mortality ; Ovarian Neoplasms/mortality ; Ovarian Neoplasms/pathology ; Retrospective Studies ; Treatment Outcome

Czasopismo naukowe

na półce

Pełny tekst Szczegóły

Skocz do pozycji: 15.

Tytuł:: Construction of Immune-Associated Nomogram for Predicting the Recurrence Survival Risk of Stage I Cervical Cancer.
Autorzy:: Wang Y; Sanquan College of Xinxiang Medical University, West of Changjiang Avenue, Pingyuan New Area, Xinxiang City, Henan Province, China.
Zhang L; Sanquan College of Xinxiang Medical University, West of Changjiang Avenue, Pingyuan New Area, Xinxiang City, Henan Province, China.
Wang B; Sanquan College of Xinxiang Medical University, West of Changjiang Avenue, Pingyuan New Area, Xinxiang City, Henan Province, China.
Cheng Y; Sanquan College of Xinxiang Medical University, West of Changjiang Avenue, Pingyuan New Area, Xinxiang City, Henan Province, China.; Pokaż więcej
Źródło:: BioMed research international [Biomed Res Int] 2021 Jul 09; Vol. 2021, pp. 6699131. Date of Electronic Publication: 2021 Jul 09 (Print Publication: 2021).
Typ publikacji:: Journal Article
MeSH Terms:: Nomograms*
Neoplasm Recurrence, Local/*pathology
Uterine Cervical Neoplasms/*immunology
Uterine Cervical Neoplasms/*pathology
Disease-Free Survival ; Female ; Gene Expression Regulation, Neoplastic ; Humans ; Kaplan-Meier Estimate ; Multivariate Analysis ; Neoplasm Recurrence, Local/genetics ; Neoplasm Staging ; Proportional Hazards Models ; ROC Curve ; Reproducibility of Results ; Risk Factors ; Signal Transduction/genetics ; Survival Analysis ; Transcriptome ; Uterine Cervical Neoplasms/genetics

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 16.

Tytuł:: Expression of phosphorylated p21-activated kinase 4 is associated with aggressive histologic characteristics and poor prognosis in patients with surgically treated renal cell carcinoma.
Autorzy:: Kang HW; Department of Urology, Chungbuk National University Hospital, College of Medicine, Chungbuk National University, Cheongju, Korea.
Piao XM; Department of Urology, Chungbuk National University Hospital, College of Medicine, Chungbuk National University, Cheongju, Korea.
Lee HY; Department of Urology, Chungbuk National University Hospital, College of Medicine, Chungbuk National University, Cheongju, Korea.
Kim K; Department of Urology, Chungbuk National University Hospital, College of Medicine, Chungbuk National University, Cheongju, Korea.
Seo SP; Department of Urology, Chungbuk National University Hospital, College of Medicine, Chungbuk National University, Cheongju, Korea.
Ha YS; Department of Urology, School of Medicine, Kyungpook National University, Daegu, Korea.
Kim YU; Department of Urology, School of Medicine, Yeungnam University, Daegu, Korea.
Kim WT; Department of Urology, Chungbuk National University Hospital, College of Medicine, Chungbuk National University, Cheongju, Korea.
Kim YJ; Department of Urology, Chungbuk National University Hospital, College of Medicine, Chungbuk National University, Cheongju, Korea.
Lee SC; Department of Urology, Chungbuk National University Hospital, College of Medicine, Chungbuk National University, Cheongju, Korea.
Kim WJ; Department of Urology, Chungbuk National University Hospital, College of Medicine, Chungbuk National University, Cheongju, Korea.
Shin EY; Department of Biochemistry and Medical Research Center, College of Medicine, Chungbuk National University, Cheongju, Korea.
Kim EG; Department of Biochemistry and Medical Research Center, College of Medicine, Chungbuk National University, Cheongju, Korea. .
Yun SJ; Department of Urology, Chungbuk National University Hospital, College of Medicine, Chungbuk National University, Cheongju, Korea. .; Pokaż więcej
Źródło:: Investigative and clinical urology [Investig Clin Urol] 2021 Jul; Vol. 62 (4), pp. 399-407. Date of Electronic Publication: 2021 May 17.
Typ publikacji:: Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:: Carcinoma, Renal Cell/*metabolism
Carcinoma, Renal Cell/*pathology
Kidney Neoplasms/*metabolism
Kidney Neoplasms/*pathology
Neoplasm Recurrence, Local/*metabolism
p21-Activated Kinases/*metabolism
Aged ; Carcinoma, Renal Cell/surgery ; Cell Nucleus/metabolism ; Cytoplasm/metabolism ; Female ; Humans ; Kaplan-Meier Estimate ; Kidney Neoplasms/surgery ; Male ; Middle Aged ; Neoplasm Grading ; Neoplasm Staging ; Phosphorylation ; Prognosis ; Proportional Hazards Models ; Survival Rate

Czasopismo naukowe

na półce

Pełny tekst Szczegóły

Skocz do pozycji: 17.

Tytuł:: Stratifying risk for multiple, recurrent, and large (≥3 cm) Ta, G1/G2 tumors in non-muscle-invasive bladder cancer.
Autorzy:: Suh J; Department of Urology, Asan Medical Center, Seoul, Korea.
Jung JH; Seoul Leaders Urology Clinic, Seoul, Korea.
Kwak C; Department of Urology, Seoul National University Hospital, Seoul, Korea.; Department of Urology, Seoul National University College of Medicine, Seoul, Korea.
Kim HH; Department of Urology, Seoul National University Hospital, Seoul, Korea.; Department of Urology, Seoul National University College of Medicine, Seoul, Korea.
Ku JH; Department of Urology, Seoul National University Hospital, Seoul, Korea.; Department of Urology, Seoul National University College of Medicine, Seoul, Korea. .; Pokaż więcej
Źródło:: Investigative and clinical urology [Investig Clin Urol] 2021 Jul; Vol. 62 (4), pp. 408-415.
Typ publikacji:: Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:: Disease Progression*
Carcinoma, Transitional Cell/*pathology
Neoplasm Recurrence, Local/*pathology
Neoplasms, Second Primary/*pathology
Urinary Bladder Neoplasms/*pathology
Adjuvants, Immunologic/therapeutic use ; Aged ; BCG Vaccine/therapeutic use ; Carcinoma, Transitional Cell/drug therapy ; Carcinoma, Transitional Cell/surgery ; Chemotherapy, Adjuvant ; Female ; Follow-Up Studies ; Humans ; Kaplan-Meier Estimate ; Male ; Middle Aged ; Myalgia/pathology ; Neoplasm Staging ; Progression-Free Survival ; Proportional Hazards Models ; Risk Assessment/methods ; Survival Rate ; Tumor Burden ; Urinary Bladder Neoplasms/drug therapy ; Urinary Bladder Neoplasms/surgery

Czasopismo naukowe

na półce

Pełny tekst Szczegóły

Skocz do pozycji: 18.

Tytuł:: Therapeutic method for early-stage second primary non-small lung cancer: analysis of a population-based database.
Autorzy:: Chen C; The Second Affiliated Hospital, Zhejiang University School of Medicine, No. 88 Jiefang road, Hangzhou City, 310000, Zhejiang Province, China.
Wu Z; The Second Affiliated Hospital, Zhejiang University School of Medicine, No. 88 Jiefang road, Hangzhou City, 310000, Zhejiang Province, China.
Wu Z; School of Electrical and Information Engineering, AnHui University of Technology, Maanshan, China.
Wu C; The Second Affiliated Hospital, Zhejiang University School of Medicine, No. 88 Jiefang road, Hangzhou City, 310000, Zhejiang Province, China.
Wang Q; The Second Affiliated Hospital, Zhejiang University School of Medicine, No. 88 Jiefang road, Hangzhou City, 310000, Zhejiang Province, China.
Zhan T; The Second Affiliated Hospital, Zhejiang University School of Medicine, No. 88 Jiefang road, Hangzhou City, 310000, Zhejiang Province, China.
Dong L; The Second Affiliated Hospital, Zhejiang University School of Medicine, No. 88 Jiefang road, Hangzhou City, 310000, Zhejiang Province, China.
Fang S; The Second Affiliated Hospital, Zhejiang University School of Medicine, No. 88 Jiefang road, Hangzhou City, 310000, Zhejiang Province, China.
Wu M; The Second Affiliated Hospital, Zhejiang University School of Medicine, No. 88 Jiefang road, Hangzhou City, 310000, Zhejiang Province, China. .; Pokaż więcej
Źródło:: BMC cancer [BMC Cancer] 2021 Jun 04; Vol. 21 (1), pp. 666. Date of Electronic Publication: 2021 Jun 04.
Typ publikacji:: Journal Article
MeSH Terms:: Carcinoma, Non-Small-Cell Lung/*therapy
Lung Neoplasms/*surgery
Neoplasm Recurrence, Local/*epidemiology
Neoplasms, Second Primary/*surgery
Pneumonectomy/*methods
Adult ; Carcinoma, Non-Small-Cell Lung/diagnosis ; Carcinoma, Non-Small-Cell Lung/mortality ; Carcinoma, Non-Small-Cell Lung/pathology ; Disease-Free Survival ; Female ; Follow-Up Studies ; Humans ; Kaplan-Meier Estimate ; Lung/pathology ; Lung Neoplasms/diagnosis ; Lung Neoplasms/mortality ; Lung Neoplasms/pathology ; Male ; Middle Aged ; Neoplasm Recurrence, Local/prevention & control ; Neoplasm Staging ; Neoplasms, Second Primary/diagnosis ; Neoplasms, Second Primary/mortality ; Neoplasms, Second Primary/pathology ; Pneumonectomy/statistics & numerical data ; Prognosis ; Retrospective Studies ; SEER Program/statistics & numerical data ; Survival Rate ; Time Factors

Czasopismo naukowe

na półce

Pełny tekst Szczegóły

Skocz do pozycji: 19.

Tytuł:: Genetic analysis of sinonasal undifferentiated carcinoma discovers recurrent SWI/SNF alterations and a novel PGAP3-SRPK1 fusion gene.
Autorzy:: Heft Neal ME; Department of Otolaryngology - Head and Neck Surgery, University of Michigan, 1150 E. Medical Center Dr., 9301B MSRB3, Ann Arbor, MI, 48109-0602, USA.
Birkeland AC; Department of Otolaryngology - Head and Neck Surgery, University of Michigan, 1150 E. Medical Center Dr., 9301B MSRB3, Ann Arbor, MI, 48109-0602, USA.
Bhangale AD; Department of Otolaryngology - Head and Neck Surgery, University of Michigan, 1150 E. Medical Center Dr., 9301B MSRB3, Ann Arbor, MI, 48109-0602, USA.
Zhai J; Department of Biostatistics, University of Michigan, Ann Arbor, MI, USA.
Kulkarni A; Department of Otolaryngology - Head and Neck Surgery, University of Michigan, 1150 E. Medical Center Dr., 9301B MSRB3, Ann Arbor, MI, 48109-0602, USA.
Foltin SK; Department of Otolaryngology - Head and Neck Surgery, University of Michigan, 1150 E. Medical Center Dr., 9301B MSRB3, Ann Arbor, MI, 48109-0602, USA.
Jewell BM; Department of Otolaryngology - Head and Neck Surgery, University of Michigan, 1150 E. Medical Center Dr., 9301B MSRB3, Ann Arbor, MI, 48109-0602, USA.
Ludwig ML; Department of Otolaryngology - Head and Neck Surgery, University of Michigan, 1150 E. Medical Center Dr., 9301B MSRB3, Ann Arbor, MI, 48109-0602, USA.; Program in Cellular and Molecular Biology, University of Michigan, 1150 E. Medical Center Dr., 9301B MSRB3, Ann Arbor, MI, 48109-0602, USA.
Pinatti L; Department of Otolaryngology - Head and Neck Surgery, University of Michigan, 1150 E. Medical Center Dr., 9301B MSRB3, Ann Arbor, MI, 48109-0602, USA.; Program in Cancer Biology, University of Michigan, Ann Arbor, MI, USA.
Jiang H; Department of Biostatistics, University of Michigan, Ann Arbor, MI, USA.; Rogel Cancer Center, University of Michigan Medical School, 1150 E. Medical Center Dr., 9301B MSRB3, Ann Arbor, MI, 48109-0602, USA.
McHugh JB; Rogel Cancer Center, University of Michigan Medical School, 1150 E. Medical Center Dr., 9301B MSRB3, Ann Arbor, MI, 48109-0602, USA.; Department of Pathology, University of Michigan, Ann Arbor, MI, USA.
Marentette L; Department of Otolaryngology - Head and Neck Surgery, University of Michigan, 1150 E. Medical Center Dr., 9301B MSRB3, Ann Arbor, MI, 48109-0602, USA.; Rogel Cancer Center, University of Michigan Medical School, 1150 E. Medical Center Dr., 9301B MSRB3, Ann Arbor, MI, 48109-0602, USA.
McKean EL; Department of Otolaryngology - Head and Neck Surgery, University of Michigan, 1150 E. Medical Center Dr., 9301B MSRB3, Ann Arbor, MI, 48109-0602, USA.; Rogel Cancer Center, University of Michigan Medical School, 1150 E. Medical Center Dr., 9301B MSRB3, Ann Arbor, MI, 48109-0602, USA.
Brenner JC; Department of Otolaryngology - Head and Neck Surgery, University of Michigan, 1150 E. Medical Center Dr., 9301B MSRB3, Ann Arbor, MI, 48109-0602, USA. .; Program in Cellular and Molecular Biology, University of Michigan, 1150 E. Medical Center Dr., 9301B MSRB3, Ann Arbor, MI, 48109-0602, USA. .; Rogel Cancer Center, University of Michigan Medical School, 1150 E. Medical Center Dr., 9301B MSRB3, Ann Arbor, MI, 48109-0602, USA. .; Department of Pharmacology, University of Michigan, 1150 E. Medical Center Dr., 9301B MSRB3, Ann Arbor, MI, 48109-0602, USA. .; Pokaż więcej
Źródło:: BMC cancer [BMC Cancer] 2021 May 29; Vol. 21 (1), pp. 636. Date of Electronic Publication: 2021 May 29.
Typ publikacji:: Journal Article
MeSH Terms:: Carboxylic Ester Hydrolases/*genetics
Carcinoma/*genetics
Maxillary Sinus Neoplasms/*genetics
Neoplasm Recurrence, Local/*epidemiology
Oncogene Proteins, Fusion/*genetics
Protein Serine-Threonine Kinases/*genetics
Receptors, Cell Surface/*genetics
Adult ; Aged ; Aged, 80 and over ; Carcinoma/mortality ; Carcinoma/therapy ; Cell Line, Tumor ; Chemoradiotherapy, Adjuvant ; Disease-Free Survival ; Female ; Follow-Up Studies ; Gene Knockdown Techniques ; Humans ; Kaplan-Meier Estimate ; Male ; Maxillary Sinus Neoplasms/mortality ; Maxillary Sinus Neoplasms/therapy ; Middle Aged ; Neoplasm Recurrence, Local/genetics ; Retrospective Studies ; Young Adult
SCR Disease Name:: Sinonasal undifferentiated carcinoma

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 20.

Tytuł:: The tumor immune microenvironment and immune-related signature predict the chemotherapy response in patients with osteosarcoma.
Autorzy:: He L; Department of Orthopaedics, The Second Affiliated Hospital of Fujian Medical University, Quanzhou, Fujian, China.
Yang H; Department of Ultrasound, The Second Affiliated Hospital of Fujian Medical University, Quanzhou, Fujian, China.
Huang J; Department of General Surgery, The Second Affiliated Hospital of Fujian Medical University, Quanzhou, 362000, Fujian, China. jingshan_.; Pokaż więcej
Źródło:: BMC cancer [BMC Cancer] 2021 May 21; Vol. 21 (1), pp. 581. Date of Electronic Publication: 2021 May 21.
Typ publikacji:: Journal Article; Validation Study
MeSH Terms:: Antineoplastic Combined Chemotherapy Protocols/*pharmacology
Biomarkers, Tumor/*genetics
Bone Neoplasms/*drug therapy
Neoplasm Recurrence, Local/*epidemiology
Osteosarcoma/*drug therapy
Tumor Microenvironment/*immunology
Adolescent ; Adult ; Aged ; Antineoplastic Combined Chemotherapy Protocols/therapeutic use ; Bone Neoplasms/genetics ; Bone Neoplasms/immunology ; Bone Neoplasms/mortality ; Child ; Child, Preschool ; Disease-Free Survival ; Drug Resistance, Neoplasm/genetics ; Drug Resistance, Neoplasm/immunology ; Female ; Gene Expression Profiling ; Gene Expression Regulation, Neoplastic/immunology ; Humans ; Kaplan-Meier Estimate ; Male ; Middle Aged ; Neoplasm Recurrence, Local/genetics ; Neoplasm Recurrence, Local/immunology ; Osteosarcoma/genetics ; Osteosarcoma/immunology ; Osteosarcoma/mortality ; Prognosis ; ROC Curve ; Retrospective Studies ; Risk Factors ; Survival Rate ; Tumor Microenvironment/genetics ; Young Adult

Czasopismo naukowe

na półce

Pełny tekst Szczegóły

Informacja

Wyszukujesz frazę ""Kaplan-Meier Estimate"" wg kryterium: Temat

Źródło danych

Ogranicz do:

Ogranicz do bazy

Typ dokumentu

Temat

Wydawca

Publikacja

Język